PCVX
No price yet
Announcements
Nothing here yet
Daily updates
- Vaxcyte reported positive top-line Phase 3 OPUS-1 results for VAX-31, meeting primary safety, immunogenicity, and immunobridging targets versus PCV20 and PCV21.Oct 5, 2026
- Vaxcyte reported positive Phase 3 OPUS-1 results for VAX-31, meeting primary safety, immunogenicity, and immunobridging goals versus PCV20 and PCV21.Oct 5, 2026
FDA designations
Nothing here yet
News
- Vaxcyte shares surge after near-best-case Phase 3 data show its next-generation pneumococcal vaccine matches Pfizer and Merck vaccines against nearly all bacterial strainsOct 11, 2026
- Vaxcyte reports positive topline results from the pivotal Phase 3 OPUS-1 trial of its 31-valent pneumococcal vaccine VAX-31Oct 5, 2026
- Vaxcyte completed enrollment in Phase 3 OPUS-1 and OPUS-2 trials of VAX-31 for preventing invasive pneumococcal disease and pneumonia in adultsMar 23, 2026
- Vaxcyte advanced adult and infant programs for next-generation VAX-31 pneumococcal vaccineJan 23, 2026
- Vaxcyte advances VAX-31 infant Phase 2 dose-finding study with first participants receiving optimized doseSep 3, 2025